SinoMab BioScience Gross margin
What is the Gross margin of SinoMab BioScience?
The Gross margin of SinoMab BioScience Limited is 78.59%
What is the definition of Gross margin?
Gross margin is the difference between revenue and cost of goods sold, divided by revenue, and expressed as a percentage.
lfy (last fiscal year)
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Gross margin of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with gross margin similar to SinoMab BioScience
- Rua Life Sciences Plc has Gross margin of 78.54%
- Acrow Formwork and Construction Services has Gross margin of 78.56%
- Uniti has Gross margin of 78.57%
- LifeTech Scientific has Gross margin of 78.57%
- Servicenow Dl ,001 has Gross margin of 78.59%
- ServiceNow Inc has Gross margin of 78.59%
- SinoMab BioScience has Gross margin of 78.59%
- Tera Software has Gross margin of 78.59%
- i-nexus Global plc has Gross margin of 78.59%
- F-Secure Oyj has Gross margin of 78.60%
- Magellan has Gross margin of 78.61%
- Prozone Intu Properties has Gross margin of 78.63%
- Pandora AS has Gross margin of 78.63%